Trial intelligence / Profile preview

CVD 1208S vaccine for Shigella flexneri 2a prevention

NCT00866242Phase 2Terminated

Sponsor
University of Maryland, Baltimore
Start
Jan 2010
Primary completion
Feb 2010
Modality
Drug Delivery Systems, Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 2, open-label trial of CVD 1208S in shigellosis, sponsored by University of Maryland, Baltimore. Started Jan 2010; status: terminated.

02

Drugs

CVD 1208S
03

Conditions

shigellosis

Beyond the preview

Go deeper on NCT00866242.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00866242.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call